Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer

Kelly R. Haisley, James Dolan, Susan Olson, Sergio A. Toledo-Valdovinos, Kyle D. Hart, Gennadiy Bakis, Brintha Enestvedt, John Hunter

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Sponge cytology is a novel screening tool for esophageal cancer but has been unable to be validated for widespread use. Our aim was to apply fluorescent in situ hybridization to sponge cytology samples in order to evaluate the safety and efficacy of this modality in screening for esophageal cancer. Materials and Methods: At a single, multidisciplinary, NCI-designated cancer center, patients completed sponge cytology sampling prior to upper endoscopy. Samples were analyzed by p53 fluorescent in situ hybridization, and results were compared to the endoscopic diagnosis. Results: Fifty patients were enrolled (96 % Caucasian, 68 % male, median age of 67). All patients successfully swallowed the capsule. No complications (string breakage, bleeding, mucosal injury) occurred. Endoscopy revealed that 38 % had normal esophageal mucosa and 62 % had an esophageal mucosal abnormality. In total, six samples demonstrated p53 loss (94 % specificity for any abnormality). The sensitivity of the p53 fluorescent in situ hybridization probe was13.3 % for any abnormality, 10 % for intestinal metaplasia, and 0 % for dysplasia or esophageal cancer. Discussion: Esophageal sponge cytology is a promising, safe, and tolerable method for collecting esophageal cell samples. However, our data suggest that p53 fluorescent in situ hybridization does not improve the sensitivity for detecting cancer in these samples.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Gastrointestinal Surgery
DOIs
StateAccepted/In press - Aug 25 2016

Fingerprint

Porifera
Esophageal Neoplasms
Fluorescence In Situ Hybridization
Early Detection of Cancer
Cell Biology
Endoscopy
Metaplasia
Capsules
Neoplasms
Hemorrhage
Safety
Wounds and Injuries

Keywords

  • Esophageal cancer
  • Esophageal sponge
  • Fluorescent in situ hybridization
  • Oesophageal cancer
  • Screening

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Gastroenterology

Cite this

Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer. / Haisley, Kelly R.; Dolan, James; Olson, Susan; Toledo-Valdovinos, Sergio A.; Hart, Kyle D.; Bakis, Gennadiy; Enestvedt, Brintha; Hunter, John.

In: Journal of Gastrointestinal Surgery, 25.08.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{b7fd0e2942284e71860790a056906b68,
title = "Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer",
abstract = "Introduction: Sponge cytology is a novel screening tool for esophageal cancer but has been unable to be validated for widespread use. Our aim was to apply fluorescent in situ hybridization to sponge cytology samples in order to evaluate the safety and efficacy of this modality in screening for esophageal cancer. Materials and Methods: At a single, multidisciplinary, NCI-designated cancer center, patients completed sponge cytology sampling prior to upper endoscopy. Samples were analyzed by p53 fluorescent in situ hybridization, and results were compared to the endoscopic diagnosis. Results: Fifty patients were enrolled (96 {\%} Caucasian, 68 {\%} male, median age of 67). All patients successfully swallowed the capsule. No complications (string breakage, bleeding, mucosal injury) occurred. Endoscopy revealed that 38 {\%} had normal esophageal mucosa and 62 {\%} had an esophageal mucosal abnormality. In total, six samples demonstrated p53 loss (94 {\%} specificity for any abnormality). The sensitivity of the p53 fluorescent in situ hybridization probe was13.3 {\%} for any abnormality, 10 {\%} for intestinal metaplasia, and 0 {\%} for dysplasia or esophageal cancer. Discussion: Esophageal sponge cytology is a promising, safe, and tolerable method for collecting esophageal cell samples. However, our data suggest that p53 fluorescent in situ hybridization does not improve the sensitivity for detecting cancer in these samples.",
keywords = "Esophageal cancer, Esophageal sponge, Fluorescent in situ hybridization, Oesophageal cancer, Screening",
author = "Haisley, {Kelly R.} and James Dolan and Susan Olson and Toledo-Valdovinos, {Sergio A.} and Hart, {Kyle D.} and Gennadiy Bakis and Brintha Enestvedt and John Hunter",
year = "2016",
month = "8",
day = "25",
doi = "10.1007/s11605-016-3239-3",
language = "English (US)",
pages = "1--7",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",

}

TY - JOUR

T1 - Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer

AU - Haisley, Kelly R.

AU - Dolan, James

AU - Olson, Susan

AU - Toledo-Valdovinos, Sergio A.

AU - Hart, Kyle D.

AU - Bakis, Gennadiy

AU - Enestvedt, Brintha

AU - Hunter, John

PY - 2016/8/25

Y1 - 2016/8/25

N2 - Introduction: Sponge cytology is a novel screening tool for esophageal cancer but has been unable to be validated for widespread use. Our aim was to apply fluorescent in situ hybridization to sponge cytology samples in order to evaluate the safety and efficacy of this modality in screening for esophageal cancer. Materials and Methods: At a single, multidisciplinary, NCI-designated cancer center, patients completed sponge cytology sampling prior to upper endoscopy. Samples were analyzed by p53 fluorescent in situ hybridization, and results were compared to the endoscopic diagnosis. Results: Fifty patients were enrolled (96 % Caucasian, 68 % male, median age of 67). All patients successfully swallowed the capsule. No complications (string breakage, bleeding, mucosal injury) occurred. Endoscopy revealed that 38 % had normal esophageal mucosa and 62 % had an esophageal mucosal abnormality. In total, six samples demonstrated p53 loss (94 % specificity for any abnormality). The sensitivity of the p53 fluorescent in situ hybridization probe was13.3 % for any abnormality, 10 % for intestinal metaplasia, and 0 % for dysplasia or esophageal cancer. Discussion: Esophageal sponge cytology is a promising, safe, and tolerable method for collecting esophageal cell samples. However, our data suggest that p53 fluorescent in situ hybridization does not improve the sensitivity for detecting cancer in these samples.

AB - Introduction: Sponge cytology is a novel screening tool for esophageal cancer but has been unable to be validated for widespread use. Our aim was to apply fluorescent in situ hybridization to sponge cytology samples in order to evaluate the safety and efficacy of this modality in screening for esophageal cancer. Materials and Methods: At a single, multidisciplinary, NCI-designated cancer center, patients completed sponge cytology sampling prior to upper endoscopy. Samples were analyzed by p53 fluorescent in situ hybridization, and results were compared to the endoscopic diagnosis. Results: Fifty patients were enrolled (96 % Caucasian, 68 % male, median age of 67). All patients successfully swallowed the capsule. No complications (string breakage, bleeding, mucosal injury) occurred. Endoscopy revealed that 38 % had normal esophageal mucosa and 62 % had an esophageal mucosal abnormality. In total, six samples demonstrated p53 loss (94 % specificity for any abnormality). The sensitivity of the p53 fluorescent in situ hybridization probe was13.3 % for any abnormality, 10 % for intestinal metaplasia, and 0 % for dysplasia or esophageal cancer. Discussion: Esophageal sponge cytology is a promising, safe, and tolerable method for collecting esophageal cell samples. However, our data suggest that p53 fluorescent in situ hybridization does not improve the sensitivity for detecting cancer in these samples.

KW - Esophageal cancer

KW - Esophageal sponge

KW - Fluorescent in situ hybridization

KW - Oesophageal cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84983450537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983450537&partnerID=8YFLogxK

U2 - 10.1007/s11605-016-3239-3

DO - 10.1007/s11605-016-3239-3

M3 - Article

C2 - 27561634

AN - SCOPUS:84983450537

SP - 1

EP - 7

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

ER -